Director McNamara buys 10,000 RCEL shares at $4.50 amid -69.1% decline from 52-week high; stock down 19.0% in 30 days.
McNamara (Director) purchased 10,000 shares at $4.50 on 2025-08-28, increasing his holdings by 13.0% to 86,771 shares total. The purchase occurs at $4.50 while the current price is $4.34, and the stock is -69.1% from its 52-week high of $14.06 and down 19.0% over 30 days. However, McNamara's cross-ticker track record shows 3 prior buys with an average 90-day return of -32.0% and a 90-day win rate of 0.00%, suggesting a pattern of purchasing before further declines. At RCEL specifically, his 2 prior measurable buys (2025-03-06 and 2025-02-20) both delivered negative returns at the 90-day mark (-28.6% and -35.4% respectively), with 0 of 2 being well-timed. The company remains unprofitable with a net loss of -$9.9M on quarterly revenue of $18.4M, despite 28.1% annual revenue growth. The timing and context raise questions about conviction in a fundamentally challenged asset trading near recent lows.
Director McNamara buys 10,000 RCEL shares at $5.00 amid -66.6% decline from 52-week high; prior same-ticker buys underwater.
Director Robert McNamara purchased 10,000 shares of AVITA Medical (RCEL) at $5.00 on 2025-08-19, increasing his holdings by 15.0% to 76.8K shares. The stock is currently trading at $4.69, down 66.6% from its 52-week high of $14.06 and down 10.0% over the past 30 days. Notably, McNamara's two prior purchases at RCEL (on 2025-03-06 and 2025-02-20) both remain significantly underwater at the 90-day mark, with negative 90-day returns of -28.6% and -35.4% respectively, and his cross-ticker buy history shows 0 of 2 prior trades with positive 90-day outcomes (average 90d return: -32.0%). The company is unprofitable with net income of -$9.9M against $18.4M quarterly revenue, although annual revenue growth stands at +28.1%. This purchase occurs within a context of persistent stock deterioration and a demonstrated pattern of poorly-timed acquisitions at this ticker.
Director McNamara buys 11,000 RCEL shares at $8.30, expanding stake 24.0% as stock trades -51.4% from 52-week high
McNamara, a Director, purchased 11,000 shares at $8.30 on 2025-03-06, increasing his holdings from 45.7K to 56.7K shares (+24.0%). This acquisition occurs while RCEL trades at $8.32 current price, down -51.4% from its 52-week high of $17.13 and -37.0% over the past 90 days. The company reported $19.5M revenue in the latest quarter with -$16.2M net income, reflecting ongoing unprofitability despite +28.1% annual revenue growth. McNamara's prior transaction history at RCEL (one buy on 2025-02-20) is not yet measurable at the 90-day mark, providing limited basis to assess timing patterns. The concentration of buys at depressed valuations warrants observation of whether this director perceives undervaluation or oversold conditions, though the company's negative earnings profile remains a material consideration for investors.
Director Robert McNamara bought 10,000 shares of RCEL at $10.09 on 2025-02-20; holdings now 45,749 shares (+28.0%)
Director Robert McNamara purchased 10,000 shares at $10.09, increasing his stake by 28.0% to 45,749 shares post-transaction. The purchase occurred when the stock was trading -45.7% from its 52-week high of $18.31, following a -25.4% decline over the preceding 90 days. The company reported latest-quarter revenue of $19.5M with net income of $-16.2M, reflecting ongoing unprofitability despite 28.1% annual revenue growth. The transaction does not directly resolve investor questions about RCEL's path to profitability or cash burn trajectory, but the director's commitment of $100,900 occurs amid depressed valuation relative to recent trading history and net losses in the most recent fiscal year.
